Neptune Medical

Neptune Medical is a medical device company specializing in innovative gastrointestinal (GI) technologies. The company's core offering is based on its proprietary Dynamic Rigidization technology, which allows thin-walled tubes such as overtubes, catheters, or cannulae to instantly toggle between flexible and rigid states. Neptune Medical's first FDA-cleared product, Pathfinder, is an advanced endoscopy device designed to enhance endoscope control during GI procedures. Pathfinder is a novel rigidizing overtube that manages loop formation, facilitates navigation to target areas, and controls the endoscope tip for both diagnostic and therapeutic GI procedures, including colonoscopies. The device has been recognized for its ability to stabilize endoscopes, prevent looping, and enable the completion of challenging procedures with relative ease. As of August 2024, Neptune Medical expanded its focus to include robotics for GI diseases. This strategic shift was marked by the appointment of Dr. Fred Moll, a pioneer in medical robotics, as Chairman of the Board. The company's subsidiary, Triton Medical Robotics, is developing a fully flexible medical robot aimed at enabling doctors to reach deep into human anatomy, potentially disrupting flexible endoscopy and setting new standards in patient outcomes. In August 2024, Neptune Medical completed a Series D financing round of USD 97 million, which strengthened its position in the GI-focused medical device market. Simultaneously, the company announced the successful spinout of its subsidiary, Jupiter Endovascular, allowing Neptune Medical to sharpen its focus on GI robotics while enabling Jupiter to innovate in endovascular treatments.

Key customers and partnerships

Neptune Medical's Pathfinder device has been adopted by a growing list of leading US hospitals and academic medical centers. These healthcare providers have reported successful use of Pathfinder in various challenging procedures, including deep retrograde enteroscopy, colonic EMR, and cases involving altered anatomy. In August 2024, Neptune Medical received significant investment participation from Sonder Capital and Olympus Corporation of the Americas, indicating strategic partnerships with these entities.